Back to Results
First PageMeta Content
Organofluorides / Pyridines / Amides / Organochlorides / Sorafenib / Onyx Pharmaceuticals / Renal cell carcinoma / Hepatocellular carcinoma / Thyroid cancer / Chemistry / Medicine / Organic chemistry


Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug Application for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer Whippany
Add to Reading List

Document Date: 2013-11-08 16:26:51


Open Document

File Size: 186,33 KB

Share Result on Facebook

City

South San Francisco / /

Company

RAI / Bayer HealthCare Pharmaceuticals Inc. / Onyx Pharmaceuticals Inc. / Bayer HealthCare LLC / Danielle Bertrand Onyx Pharmaceuticals Inc. / Bayer AG / Onyx Pharmaceuticals / Twitter / Bayer HealthCare Pharmaceuticals / Investors Amy Figueroa Onyx Pharmaceuticals Inc. / Media Rose Talarico Bayer HealthCare Pharmaceuticals / /

Country

United States / /

Event

FDA Phase / /

IndustryTerm

pharmaceutical / healthcare / Treatment of Differentiated Thyroid Cancer / biopharmaceutical / pharmaceuticals / /

MedicalCondition

unresectable hepatocellular carcinoma / differentiated thyroid cancer / congenital long QT syndrome / fastest-increasing cancer / Drug-induced hepatitis / refractory thyrOid caNcer / Solid Tumors / nausea / alopecia / toxic epidermal necrolysis / J Cancer / bradyarrhythmias / metastatic disease / Stevens-Johnson Syndrome / fatigue / non-small cell lung cancer / differentiated thyroid cancers / diarrhea / Illness / Thyroid Cancer Thyroid cancer / cancers / abdominal pain / squamous cell lung cancer / tumor / congestive heart failure / Hypertension / common cancer / cancer / Disease / Radioiodine Nonresponsive Disease / myocardial infarction / hepatic failure / diseases / advanced renal cell carcinoma / thyroid cancer / rash / refractory differentiated thyroid cancer / /

MedicalTreatment

antibiotics / chemotherapy / Surgical Treatment / innovative therapies / /

Organization

World Health Organization / Nexavar administration / U.S. Food and Drug Administration / FDA / /

Person

Pablo J. Cagnoni / Marlon A. Guerrero / Raghunandan Venkat / Lucia Brilli / Maria E. Cabanillas / Pamela A. Cyrus / Naifa Lamki Busaidy / /

/

Position

Vice President / Global Research & Development / General / Vice President and Head of U.S. Medical Affairs / Executive Vice President / /

Product

carboplatin / cisplatin / paclitaxel / Nexavar / Prescription Drug / Nexavar® (sorafenib) tablets / Treatment / /

ProvinceOrState

California / /

PublishedMedium

The Scientific World Journal / /

Technology

antibodies / pharmacokinetics / chemotherapy / /

URL

http /

SocialTag